A. Camm, G. Lip, R. Caterina, I. Savelieva, D. Atar et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation An update of the 2010 ESC Guidelines for the management of atrial fibrillationDeveloped with the special contribution of the European Heart Rhythm Association, Eur Heart J, vol.33, issue.21, pp.2719-2766, 2012.

J. Weitz, J. Eikelboom, and M. Samama, New Antithrombotic Drugs, Chest, vol.141, issue.2, pp.120-151, 2012.
DOI : 10.1378/chest.11-2294

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278067

B. Eriksson, O. Dahl, M. Huo, A. Kurth, S. Hantel et al., Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-­?NOVATE II*). A randomised, double-­?blind, non-­?inferiority trial

B. Eriksson, L. Borris, R. Friedman, S. Haas, M. Huisman et al., Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty, New England Journal of Medicine, vol.358, issue.26, pp.2765-75, 2008.
DOI : 10.1056/NEJMoa0800374

URL : http://mediatum.ub.tum.de/doc/693767/document.pdf

A. Kakkar, B. Brenner, O. Dahl, B. Eriksson, P. Mouret et al., Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, The Lancet, vol.372, issue.9632, pp.31-40, 2008.
DOI : 10.1016/S0140-6736(08)60880-6

M. Lassen, A. Gallus, G. Raskob, G. Pineo, D. Chen et al., Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement, New England Journal of Medicine, vol.363, issue.26, pp.2487-98, 2010.
DOI : 10.1056/NEJMoa1006885

M. Lassen, G. Raskob, A. Gallus, G. Pineo, D. Chen et al., Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial, The Lancet, vol.375, issue.9717, pp.807-822, 2010.
DOI : 10.1016/S0140-6736(09)62125-5

S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009.
DOI : 10.1056/NEJMoa0905561

M. Patel, K. Mahaffey, J. Garg, G. Pan, D. Singer et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011.
DOI : 10.1056/NEJMoa1009638

URL : https://hal.archives-ouvertes.fr/hal-01038111

C. Granger, J. Alexander, J. Mcmurray, R. Lopes, E. Hylek et al., Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11, pp.981-92, 2011.
DOI : 10.1056/NEJMoa1107039

E. Investigators, R. Bauersachs, S. Berkowitz, B. Brenner, H. Buller et al., Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, vol.363, issue.26, pp.2499-510, 2010.

E. Pe-investigators, H. Büller, M. Prins, A. Lensin, H. Decousus et al., Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism, New England Journal of Medicine, vol.366, issue.14, pp.1287-97, 2012.
DOI : 10.1056/NEJMoa1113572

S. Schulman, C. Kearon, A. Kakkar, P. Mismetti, S. Schellong et al., Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.361, issue.24, pp.2342-52, 2009.
DOI : 10.1056/NEJMoa0906598

URL : https://hal.archives-ouvertes.fr/ujm-00439704

G. Agnelli, H. Buller, A. Cohen, M. Curto, A. Gallus et al., Oral Apixaban for the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.369, issue.9, pp.799-808, 2013.
DOI : 10.1056/NEJMoa1302507

URL : https://hal.archives-ouvertes.fr/hal-00932477

J. Oldgren, L. Wallentin, J. Alexander, S. James, B. Jönelid et al., New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis, European Heart Journal, vol.34, issue.22, pp.1670-80
DOI : 10.1093/eurheartj/eht049

D. Fitchett, Potential role of rivaroxaban in patients with acute coronary syndrome, Drug Design, Development and Therapy, 2012.
DOI : 10.2147/DDDT.S30342

A. Cohen, T. Spiro, H. Büller, L. Haskell, D. Hu et al., Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients, New England Journal of Medicine, vol.368, issue.6, pp.513-536, 2013.
DOI : 10.1056/NEJMoa1111096

URL : https://hal.archives-ouvertes.fr/hal-00933269

S. Goldhaber, A. Leizorovicz, A. Kakkar, S. Haas, G. Merli et al., Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients, New England Journal of Medicine, vol.365, issue.23, 2011.
DOI : 10.1056/NEJMoa1110899

URL : https://hal.archives-ouvertes.fr/hal-00721937

I. and E. France, Disponible: http://insee.fr/fr/themes/document, la croissance retrouvée des espaces ruraux reste limitée à sept régions [Internet]. [consulté le 10 Octobre 2014]asp?reg_id=17&ref_id=15862&page=EL/EL205-­? 206/EL205-­?206_4.htm 28. EDO sophie. Etude comparative des conditions de vie et d'exercice des femmes médecins généralistes en milieu urbain, semi-­?urbain et rural en Isère. Faculté de medecine Lyon sud Charles Merieux, 2010.

G. Pernod, P. Albaladejo, A. Godier, C. Samama, S. Susen et al., Management of major bleeding complications and emergency surgery in patients on long-­?term treatment with direct oral anticoagulants, thrombin or factor-­?Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) -­? Ann Fr Anesthèsie Rèanimation, pp.691-700, 2013.

A. Tripodi, V. Chantarangkul, C. Guinet, and M. Samama, The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in??vitro study, Journal of Thrombosis and Haemostasis, vol.8, issue.1, 2011.
DOI : 10.1111/j.1538-7836.2010.04106.x

M. Samama, J. Martinoli, L. Leflem, C. Guinet, G. Plu-­?bureau et al., Assessment of laboratory assays to measure rivaroxaban ??? an oral, direct factor Xa inhibitor, Thrombosis and Haemostasis, vol.103, issue.4, pp.815-840, 2010.
DOI : 10.1160/TH09-03-0176

O. Grottke, J. Van-ryn, H. Spronk, and R. Rossaint, Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model, Critical Care, vol.18, issue.1, p.27, 2014.
DOI : 10.1093/bja/aes502

G. Lu, F. Deguzman, S. Hollenbach, M. Karbarz, K. Abe et al., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.48, issue.4
DOI : 10.1038/nm.3102

E. Eerenberg, P. Kamphuisen, M. Sijpkens, J. Meijers, H. Buller et al., Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects, Circulation, vol.124, issue.14, pp.1573-1582, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.029017

K. Vavra, M. Lutz, and M. Smythe, Recombinant Factor VIIa to Manage Major Bleeding from Newer Parenteral Anticoagulants, Annals of Pharmacotherapy, vol.44, issue.4, pp.718-744, 2010.
DOI : 10.1345/aph.1M447

S. Barco, Y. Cheung, J. Eikelboom, and M. Coppens, New oral anticoagulants in elderly patients, Best Practice & Research Clinical Haematology, vol.26, issue.2, pp.215-239
DOI : 10.1016/j.beha.2013.07.011

T. Larsen, L. Rasmussen, F. Skjøth, K. Due, T. Callréus et al., Efficacy and Safety of Dabigatran Etexilate and Warfarin in ???Real-World??? Patients With Atrial Fibrillation, Journal of the American College of Cardiology, vol.61, issue.22, pp.2264-73, 2013.
DOI : 10.1016/j.jacc.2013.03.020

P. Haper and L. Young, Bleeding risk with dabigatran in the frail elderly, NEJM N Engl J Med. 2012, vol.366, issue.9, pp.864-870

P. Maccallum, R. Mathur, S. Hull, K. Saja, L. Green et al., Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study, BMJ Open, vol.3, issue.9, p.3343, 2013.
DOI : 10.1136/bmjopen-2013-003343

G. Bouvenot, J. Bounhoure, J. Montastruc, and A. Vacheron, Les anticoagulants oraux directs (AOD) (antérieurement appelés " nouveaux anticoagulants oraux " ou NACO) Académie Nationale de Médecine, 2014.

J. Olesen, C. Torp-­?pedersen, M. Hansen, and G. Lip, The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0???1: A nationwide cohort study, Thrombosis and Haemostasis, vol.107, issue.6, 2012.
DOI : 10.1160/TH12-03-0175

D. Barcellona, P. Contu, G. Sorano, V. Pengo, and F. Marongiu, The management of oral anticoagulant therapy: the patient's point of view, Thromb Haemost, vol.83, issue.1, pp.49-53, 2000.

T. Lancaster, D. Singer, M. Sheehan, L. Oertel, S. Maraventano et al., The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Archives of Internal Medicine, vol.151, issue.10, pp.1944-1953, 1991.
DOI : 10.1001/archinte.151.10.1944

R. Rodriguez, M. Carrier, and P. Wells, Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?, Journal of Thrombosis and Haemostasis, vol.17, issue.2, pp.390-394, 2013.
DOI : 10.1111/jth.12086

C. Van-walraven, A. Jennings, N. Oake, D. Fergusson, and A. Forster, Effect of Study Setting on Anticoagulation Control, Chest, vol.129, issue.5, 2006.
DOI : 10.1378/chest.129.5.1155

S. Connolly, J. Pogue, J. Eikelboom, G. Flaker, P. Commerford et al., Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range, Circulation, vol.118, issue.20, pp.2029-2066, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.750000

A. Claxton, J. Cramer, and C. Pierce, A systematic review of the associations between dose regimens and medication compliance, Clinical Therapeutics, vol.23, issue.8, pp.1296-310, 2001.
DOI : 10.1016/S0149-2918(01)80109-0

P. Frappé and S. Liébart, New oral anticoagulants in primary care: The general practitioner's point of view]. Presse Médicale Paris Fr 1983, pp.1267-73, 2013.

C. Krieger, Les médecins face aux nouveaux anticoagulants. [DES de médecine générale], 2013.

F. Laliberté, M. Cloutier, W. Nelson, C. Coleman, D. Pilon et al., Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients, Current Medical Research and Opinion, vol.30, issue.7, pp.1317-1342
DOI : 10.1185/03007995.2014.907140

F. Van-de-werf, M. Brueckmann, S. Connolly, J. Friedman, C. Granger et al., A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN), American Heart Journal, vol.163, issue.6, pp.931-938
DOI : 10.1016/j.ahj.2012.03.011

J. Pink, S. Lane, M. Pirmohamed, and D. Hughes, Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses, BMJ, vol.343, issue.oct31 1, p.6333, 2011.
DOI : 10.1136/bmj.d6333

T. Wisløff, G. Hagen, and M. Klemp, Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation, PharmacoEconomics, vol.132, issue.3, pp.601-613, 2014.
DOI : 10.1007/s40273-014-0152-z

D. Cohen, Dabigatran: how the drug company withheld important analyses, BMJ, vol.349, issue.jul23 12, p.4670, 2014.
DOI : 10.1136/bmj.g4670

J. Grange, A general practitioner's one year record of adverse drug reactions

A. Bensadon, E. Marie, and A. Morelle, Rapport sur la pharmacovigilance et gouvernance de la chaîne du médicament. Inspection générale des affaires sociales, Juin, 2011.

J. Inch and M. Watson, Patient versus Healthcare Professional Spontaneous Adverse Drug Reaction Reporting, Drug Safety, vol.33, issue.462, pp.807-825, 2012.
DOI : 10.1007/BF03261977